BioNTech’s fair value estimate has been trimmed from $139.51 to $131.39, a modest cut of about 6% that reflects the latest model inputs. This shift comes as analysts reassess the story around ...

The May meeting thus serves as a ratification of BioNTech's new architecture for the post-pandemic era. The votes will legitimize the structural and financial framework designed to bridge the company ...

By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...

BioNTech will wind up its vaccine manufacturing plant in Singapore by February 2027 after a strategic review. Read more at ...

Amid growing financial concerns and US vaccine hesitancy, the German company will close its mRNA site in Southeast Asia.

The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved ...

The German biotechnology company currently employs 85 people at its manufacturing plant in Tuas.

On the heels of a comprehensive review, BioNTech has decided “to close its planned Singapore site by the end of February 2027 ...

Pfizer BioNTech halt COVID vaccine study in adults 50-64 due to slow enrollment, citing inability to generate relevant postmarketing data.

BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other ...

The founders of the biotech company that developed Comirnaty, the mRNA-based COVID-19 vaccine sold by BioNTech and Pfizer, ...